Clinical Efficacy Observation On BSPD Capsule Used For Patients Of Yang Deficiency Of The Spleen And Kidney And Blood Stasis And Turbid Phlegm Syndrome Of CKD 3 Stage

Objective: To observe the clinical effects of the patients, who have taken BuShen PaiDu(BSPD) capsule at chronic kidney disease(CKD) stage 3(the Yang deficiency of spleen and kidney and blood stasis and turbid phlegm syndrome).Methods: 50 patients at CKD stage 3, who were from January 2015 to December2015 and met the inclusion criteria, were randomly divided into 2 groups, namely, the treatme nt group and the controlled group. Two groups, of which the number are both 25 respectively,were treated with health management as well as basic therapy and the treatment group was taken BSPD capsule for oral administration for extra. After three courses of treatment(one course equals four weeks),the variation about the comprehensive clinical efficacy, score of Traditional Chinese Medicine(TCM) syndromes, serum creatinine(Scr), blood urea nitrogen(BUN), creatinine clearance rate(Ccr), cystatin C(Cys C), 24 h urinary protein excretion(Upr), Albumin(Alb), hemoglobin(Hb), triglycerides(TG) and the total cholesterol(TC)levels between the two groups were observed.Results:(1) After patients were treated for 12 weeks, the total effective rate of the treatment group(the controlled group) was 86.96%(58.33%). Hence, the curative effect of the treatment group was better than that of the control group(P<0.05).(2) After treatment,the TCM syndromes score of two groups were both reduced, however, the treatment group was much lower than the controlled group(P<0.05). The effective rate of the TCM syndromes of the treatment group(82.61%) was obviously higher than that of the controlled group(P<0.05), which was 54.17%.(3) After treatment, the level of BUN, Scr, Cys C and Upr was decreased in two groups. Though the level of Ccr was increased, the treatment group were better than the controlled group(P<0.05 or P<0.01). In addition, the level of the Hb and Alb of the patients from the treatment group was significantly increased compared with that before the treatment(P<0.05), however, the expressions of Hb and Alb in controlled group had no significant change(P>0.05). Hence, the treatment group was better than the controlled group(P<0.05). Furthermore, the level of TC and TG from two groups were both decreased after treatment. More specific, the level of the TC and TG from the treatment group was decreased greatly(P<0.01) and there is no significant statistical significance for the controlled group(P>0.05). Therefore, the treatment group was better than the controlled group(P<0.05).(4)The Blood routine as well as liver function(ALT, AST) before and after treatment in two groups were in the normal range. In the course of treatment, 3 patients with wild diarrhea have occurred, which can be relieved when the dose of the medication was deduced.Conclusions: BSPD capsule can obviously improve the clinical symptoms of CKD 3(spleen and kidney yang deficiency and blood stasis and turbid phlegm syndrome) and the life of patients. It also can improve the patient's experimental indicators and delay the progress of renal failure. The adverse reaction of the BSPD capsule is mild and safe, and can be applied to the patients with CKD 3 phase(the Yang deficiency of spleen and kidney and blood stasis and turbid phlegm syndrome).